Gut microbiota disorders and its correction

September 4, 2018
Specialities :

The pool of microbes inhabiting human body is known as microbiota. The colon is the most densely populated organ in the human body. Gut microbiota is one of the determinative factors of the human health. Intestinal bacteria play on crucial role in maintaining immune and metabolic homeostasis and protecting against pathogens. Gut microbiota disorders or dysbiosis is related to many health problems both within the gastro-intestinal tract and outside it. Prebiotics (such as inulin, oligofructose) play a key role in life support of microorganisms of a gastro-intestinal tract. Probiotics play an important role in the correction of colonic biocenosis and stimulation of vital activity of obligate microflora. Medical and prophylactic effects of probiotics include increase of resistance to infectious diseases of intestine and respiratory tract, prevention and decrease of diarrhea duration, improvement of lactose tolerance, treatment of constipation, decrease of atopic reactions tendency, etc. Lactobacillus and Bifidobacterium species are the most commonly used probiotics. Used strains can have direct effect on permeability of intestinal barrier and immunodefence components: increase of immunoglobulin A production, modify activity of phagocytes and natural killers, cytokine production. Treatment is safe for patients and well tolerated.

T.M. Bentsa

Key words: gut microbiota, dysbiosis, probiotics, Bifidobacterium, Lactobacillus, Linex Forte®.

Published: 04.09.2018


  • Bondarenko V.M., Matsulevich T.V. (2007) Disbakterioz kishechnika kak kliniko-laboratornyiy sindrom: sovremennoe sostoyanie problemyi. GEOTAR-Media, Moskva, 304 s.
  • Mechnikov I.I. (1964) Etyudyi optimizma. Nauka, Moskva, 128 s.
  • Perederiy V.G., Tkach S.M., Skopichenko S.V. (2007) Sindrom razdrazhennoy kishki kak samostoyatelnyiy diagnoz i odno iz naibolee rasprostranennyih gastroenterologicheskih zabolevaniy. Kiev, 114–132.
  • Tsimmerman Ya.S. (2013) Eubioz i disbioz zheludochno-kishechnogo trakta: mifyi i realii. Klin. meditsina, 91(5): 4–11.
  • Becattini S., Taur Y., Pamer E.G. (2016) Antibiotic-Induced Changes in the Intestinal Microbiota and Disease. Trends Mol. Med., 22(6): 458–478.
  • Bogovič Matijašić B., Obermajer T., Lipoglavšek L. et al. (2016) Effects of synbiotic fermented milk containing Lactobacillus acidophilus La-5 and Bifidobacterium animalis ssp. lactis BB-12 on the fecal microbiota of adults with irritable bowel syndrome: A randomized double-blind, placebo-controlled trial. J. Dairy Sci., 99(7): 5008–5021.
  • de Moreno de LeBlanc A., LeBlanc J.G. (2014) Effect of probiotic administration on the intestinal microbiota, current knowledge and potential applications. World J. Gastroenterol., 20(44): 16518–16528.
  • Delcenserie V., Martel D., Lamoureux M. et al. (2008) Immunomodulatory effects of probiotics in the intestinal tract. Curr. Issues Mol. Biol., 10(1–2): 37–54.
  • Eskesen D., Jespersen L., Michelsen B. et al. (2015) Effect of the probiotic strain Bifidobacterium animalis subsp. lactis, BB-12®, on defecation frequency in healthy subjects with low defecation frequency and abdominal discomfort: a randomised, double-blind, placebo-controlled, parallel-group trial. Br. J. Nutr., 114(10): 1638–1646.
  • Guarner F., Sanders M.E., Eliakim R. et al. (2017) World Gastroenterology Organisation Global Guideline: Probiotics and prebiotics. WGO, 37 p.
  • Harmsen H.J., de Goffau M.C. (2016) The Human Gut Microbiota. Adv. Exp. Med. Biol., 902: 95–108.
  • Hill C., Guarner F., Reid G. et al. (2014) Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat. Rev. Gastroenterol. Hepatol., 11(8): 506–514.
  • Isolauri E., Sütas Y., Kankaanpää P. et al. (2001) Probiotics: effects on immunity. Am. J. Clin. Nutr., 73(2 Suppl.): 444S–450S.
  • Jungersen M., Wind A., Johansen E. et al. (2014) The Science behind the Probiotic Strain Bifidobacterium animalis subsp. lactis BB-12(®). Microorganisms, 2(2): 92–110.
  • Ki Cha B., Mun Jung S., Hwan Choi C. et al. (2012) The effect of a multispecies probiotic mixture on the symptoms and fecal microbiota in diarrhea-dominant irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J. Clin. Gastroenterol., 46(3): 220–227.
  • La Fata G., Weber P., Mohajeri M.H. (2018) Probiotics and the Gut Immune System: Indirect Regulation. Probiotics Antimicrob. Proteins., 10(1): 11–21.
  • Lee N., Kim W.U. (2017) Microbiota in T-cell homeostasis and inflammatory diseases. Exp. Mol. Med., 49(5): e340.
  • Ley R.E., Lozupone C., Hamady M. et al. (2008) Worlds within worlds: evolution of the vertebrate gut microbiota. Nature Rev. Microbiol., 6: 776–788.
  • Lin M.Y., Chang F.J. (2000) Antioxidative effect of intestinal bacteria Bifidobacterium longum ATCC 15708 and Lactobacillus acidophilus ATCC 4356. Dig. Dis. Sci., 45(8): 1617–1622.
  • Nagao-Kitamoto H., Kitamoto S., Kuffa P., Kamada N. (2016) Pathogenic role of the gut microbiota in gastrointestinal diseases. Intest. Res., 14(2): 127–138.
  • Nissle A. (1916) Uber die Grundlagen einer e neuen ursachlichen Bekampfung der pathologishen Darmflora. Dtsch. Med. Wschr., 42: 1181–1184.
  • Pace F., Pace M., Quartarone G. (2015) Probiotics in digestive diseases: focus on Lactobacillus GG. Minerva Gastroenterol. Dietol., 61(4): 273–292.
  • Roberfroid M., Gibson G.R., Hoyles L. et al. (2010) Prebiotic effects: metabolic and health benefits. Br. J. Nutr., 104 Suppl. 2: S1–S63.
  • Thursby E., Juge N. (2017) Introduction to the human gut microbiota. Biochem. J., 474(11): 1823–1836.
  • Tojo R., Suárez A., Clemente M.G. et al. (2014) Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis. World J. Gastroenterol., 20(41): 15163–15176.
  • Turnbaugh P.J., Ley R.E., Hamady M. et al. (2007) The human microbiome project. Nature, 449(7164): 804–810.
  • Vandenplas Y., Huys G., Daube G. (2015) Probiotics: an update. J. Pediatr. (Rio J.), 91(1): 6–21.